The role of viral and host genetics in natural history and treatment of chronic HCV infection

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 4, 2012, Pages 413-427

  Doyle, Joseph S ^a,b,c   Hellard, Margaret E ^a,b,c   Thompson, Alexander J ^d,e,f  

^a BURNET INSTITUTE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Genetics; Genome wide association; Hepatitis C virus; IL28B; Natural history; Single nucleotide polymorphism; Treatment

Indexed keywords

ABT 072; ABT 333; ABT 450; ALPHA INTERFERON; ASUNAPREVIR; BI 207127; BOCEPREVIR; DACLATASVIR; FALDAPREVIR; HOST FACTOR; INOSINE TRIPHOSPHATE; INTERLEUKIN 28B; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ANEMIA; ANTIVIRAL THERAPY; DISEASE MARKER; DRUG DOSE REDUCTION; GENOME ANALYSIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MONOTHERAPY; NONHUMAN; REVIEW; TREATMENT OUTCOME; VIRAL GENETICS; VIRUS GENOME;

EID: 84870461293     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2012.09.004     Document Type: Article

References (113)

1. C.W. Shepard, L. Finelli, and M.J. Alter Global epidemiology of hepatitis C virus infection Lancet Infect Dis 5 9 2005 558 567
2. J.F. Perz, G.L. Armstrong, and L.A. Farrington The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide J Hepatol 45 4 2006 529 538
3. K.N. Ly, J. Xing, and R.M. Klevens The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007 Ann Intern Med 156 4 2012 271 278
4. J.M. Micallef, J.M. Kaldor, and G.J. Dore Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies J Viral Hepat 13 1 2006 34 41
5. A. Rauch, S. Gaudieri, and C. Thio Host genetic determinants of spontaneous hepatitis C clearance Pharmacogenomics 10 11 2009 1819 (19)
6. D.G. Bowen, and C.M. Walker Adaptive immune responses in acute and chronic hepatitis C virus infection Nature 436 7053 2005 946 952
7. J. Grebely, G.V. Matthews, and G.J. Dore Treatment of acute HCV infection Nat Rev Gastroenterol Hepat 8 5 2011 265 274
8. M.W. Fried Side effects of therapy of hepatitis C and their management Hepatology 36 2002 S237 S244
9. M.S. Sulkowski, C. Cooper, and B. Hunyady Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C Nat Rev Gastroenterol Hepat 8 4 2011 212 223
10. K.R. Reddy, D.R. Nelson, and S. Zeuzem Ribavirin: current role in the optimal clinical management of chronic hepatitis C J Hepatol 50 2 2009 402 411
11. A.J. Thompson, A.J. Muir, and M.S. Sulkowski Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 1 2010 120 129
12. C. Sarrazin, S. Susser, and A. Doehring Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients J Hepatol 54 3 2011 415 421
13. E. Vezali, A. Aghemo, and M. Colombo A review of the treatment of chronic hepatitis C virus infection in cirrhosis Clin Ther 32 13 2010 2117 2138
14. J.G. McHutchison, E.J. Lawitz, and M.L. Shiffman Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 6 2009 580 593
15. I.M. Jacobson, R.S. Brown Jr., and B. Freilich Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial Hepatology 46 4 2007 971 981
16. B.L. Pearlman, and N. Traub Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more Clin Infect Dis 52 7 2011 889 900
17. I.M. Jacobson, J.G. McHutchison, and G. Dusheiko Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 25 2011 2405 2416
18. S. Zeuzem, P. Andreone, and S. Pol Telaprevir for retreatment of HCV infection N Engl J Med 364 25 2011 2417 2428
19. F. Poordad, J. McCone Jr., and B.R. Bacon Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 13 2011 1195 1206
20. B.R. Bacon, S.C. Gordon, and E. Lawitz Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 13 2011 1207 1217
21. J.M. Vierling Efficacy of boceprevir in prior null responders to Peginterferon/Ribavirin: the PROVIDE Study Hepatology 54 Suppl. 1 2011 A931
22. G.R. Foster, C. Hezode, and J.P. Bronowicki Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections Gastroenterology 141 3 2011 881 889 e1
23. J.A. Howe, D. Graham, and P. McMonagle In vitro characterization of the pan-genotype activity of the HCV NS3/4a protease inhibitors boceprevir and telaprevir J Hepatol 56 Suppl. 2 2012 S329
24. M. Sulkowski, D. Gardiner, and E. Lawitz Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +/- ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3 J Hepatol 56 Suppl. 2 2012 S560
25. E.J. Gane, C.A. Stedman, and R.H. Hyland ELECTRON: once daily PSI-7977 plus RBV in HCV GT1/2/3 J Hepatol 56 Suppl. 2 2012 S438 S439
26. S. Zeuzem, V. Soriano, and T. Asselah SVR4 and SVR12 with an interferon-free regimen of BI201335 and BI207127, +/- ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: interim results of SOUND-C2 J Hepatol 56 Suppl. 2 2012 S45
27. A.S. Lok, D.F. Gardiner, and E. Lawitz Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 3 2012 216 224
28. M. Kurosaki, N. Sakamoto, and M. Iwasaki Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis J Med Virol 83 3 2011 445 452
29. Y.H. Yen, C.H. Hung, and T.H. Hu Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin Aliment Pharmacol Ther 27 1 2008 72 79
30. G. Duverlie, H. Khorsi, and S. Castelain Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity J Gen Virol 79 Pt 6 1998 1373 1381
31. S. Zeuzem, J.H. Lee, and W.K. Roth Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa Hepatology 25 3 1997 740 744
32. A. El-Shamy, M. Nagano-Fujii, and N. Sasase Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy Hepatology 48 1 2008 38 47
33. N. Akuta, F. Suzuki, and H. Sezaki Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy Intervirology 48 6 2005 372 380
34. N. Akuta, F. Suzuki, and Y. Kawamura Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels J Hepatol 46 3 2007 403 410
35. N. Akuta, F. Suzuki, and M. Hirakawa Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin Hepatology 52 2 2010 421 429
36. M.J. Donlin, N.A. Cannon, and R. Aurora Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients PLoS ONE 5 2 2010 e9032
37. R. Aurora, M.J. Donlin, and N.A. Cannon Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans J Clin Invest 119 1 2009 225 236
38. P. Halfon, and S. Locarnini Hepatitis C virus resistance to protease inhibitors J Hepatol 55 1 2011 192 206
39. J.G. McHutchison, M.P. Manns, and A.J. Muir Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
40. D.J. Bartels, Y. Zhou, and E.Z. Zhang Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects J Infect Dis 198 2008 800 807
41. T.L. Kieffer, C. Sarrazin, and J.S. Miller Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients Hepatology 46 2007 631 639
42. C. Sarrazin, and S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2 2010 447 462
43. A.J. Muir, J.D. Bornstein, and P.G. Killenberg Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites N Engl J Med 350 22 2004 2265 2271
44. L.J. Jeffers, W. Cassidy, and C.D. Howell Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 Hepatology 39 6 2004 1702 1708
45. H.S. Conjeevaram, M.W. Fried, and L.J. Jeffers Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1 Gastroenterology 131 2 2006 470 477
46. M.L. Shiffman, A.A. Mihas, and F. Millwala Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3 Am J Gastroenterol 102 4 2007 761 766
47. E.S. Lander, L.M. Linton, and B. Birren Initial sequencing and analysis of the human genome Nature 409 6822 2001 860 921
48. J. Hardy, and A. Singleton Genomewide association studies and human disease N Engl J Med 360 17 2009 1759 1768
49. International HapMap Consortium A haplotype map of the human genome Nature 437 7063 2005 1299 1320
50. D. Ge, J. Fellay, and A.J. Thompson Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 7262 2009 399 401
51. V. Suppiah, M. Moldovan, and G. Ahlenstiel IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 10 2009 1100 1104
52. Y. Tanaka, N. Nishida, and M. Sugiyama Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 10 2009 1105 1109
53. A. Rauch, Z. Kutalik, and P. Descombes Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 4 2010 1338 1345 45 e1-7
54. N. Ank, M.B. Iversen, and C. Bartholdy An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity J Immunol (Baltimore, Md 1950) 180 4 2008 2474 2485
55. M. Li, X. Liu, and Y. Zhou Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses J Leukoc Biol 86 1 2009 23 32
56. D.L. Thomas, C.L. Thio, and M.P. Martin Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 7265 2009 798 801
57. J.A. Holmes, W. Sievert, and A.J. Thompson IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection Biomark Med 5 4 2011 461 478
58. P.Y. Bochud, S. Bibert, and F. Negro IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C J Hepatol 55 5 2011 980 988
59. N.I. Rallon, S. Naggie, and J.M. Benito Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients AIDS 24 8 2010 F23 F29
60. N. Antaki, S. Bibert, and K. Kebbewar IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4 J Viral Hepat 2012 [:no-no]
61. A. Mangia, A.J. Thompson, and R. Santoro An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response Gastroenterology 139 3 2010 821 827 7 e1
62. T. Kawaoka, C.N. Hayes, and W. Ohishi Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b J Hepatol 54 3 2011 408 414
63. T.M. Scherzer, H. Hofer, and A.F. Staettermayer Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin J Hepatol 54 5 2011 866 871
64. M.L. Yu, C.F. Huang, and J.F. Huang Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients Hepatology 53 1 2011 7 13
65. J. Grebely, G.V. Matthews, and M. Hellard IL28B genotype has variable influence on early viral kinetics, but no influence on sustained virological response during treatment for recent hepatitis C virus infection J Hepatol 54 2011 S524
66. E. Jaeckel, M. Cornberg, and H. Wedemeyer Treatment of acute hepatitis C with interferon alfa-2b N Engl J Med 345 20 2001 1452 1457
67. J. Wiegand, P. Buggisch, and W. Boecher Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study Hepatology 43 2 2006 250 256
68. S.M. Kamal, A.E. Fouly, and R.R. Kamel Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response Gastroenterology 130 3 2006 632 638
69. F. Poordad, J.P. Bronowicki, and S.C. Gordon IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir combination therapy J Hepatol 54 Suppl. 1 2011 S6
70. I.M. Jacobson, I. Catlett, and P. Marcellin Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial J Hepatol 54 Suppl. 1 2011 S542 S543
71. T.W. Chu, R. Kulkarni, and E.J. Gane Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C Gastroenterology 142 4 2012 790 795
72. S. Liu, L.E. Cipriano, and M. Holodniy New protease inhibitors for the treatment of chronic hepatitis C Ann Intern Med 156 4 2012 279 290
73. S.V. Kotenko, G. Gallagher, and V.V. Baurin IFN-[lambda]s mediate antiviral protection through a distinct class II cytokine receptor complex Nat Immunol 4 1 2003 69 77
74. T. Marcello, A. Grakoui, and G. Barba-Spaeth Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics Gastroenterology 131 6 2006 1887 1898
75. S. Zeuzem, S. Arora, and B. Bacon Pegylated interferon-lambda (PegIFN-lambda) shows superior viral response with improved safety and tolerability versus PegIFNα-2a in HCV patients (Gl/2/3/4): emerge phase IIb through week 12 J Hepatol 54 Suppl. 1 2011 S538 S539
76. M. Honda, A. Sakai, and T. Yamashita Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C Gastroenterology 139 2 2010 499 509
77. T.J. Urban, A.J. Thompson, and S.S. Bradrick IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C Hepatology 52 6 2010 1888 1896
78. J. Fellay, A.J. Thompson, and D. Ge ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C Nature 464 7287 2010 405 408
79. A.J. Thompson, P.J. Clark, and A. Singh Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients J Hepatol 56 2 2012 313 319
80. A.J. Thompson, J. Fellay, and K. Patel Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction Gastroenterology 139 4 2010 1181 1189 e2
81. A.J. Thompson, R. Santoro, and V. Piazzolla Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR Hepatology 53 2 2011 389 395
82. Y. Hitomi, E.T. Cirulli, and J. Fellay Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function Gastroenterology 140 4 2011 1314 1321
83. R.A. Bull, F. Luciani, and K. McElroy Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection PLoS Pathog 7 9 2011 e1002243
84. H.L. Tillmann, A.J. Thompson, and K. Patel A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice Gastroenterology 139 5 2010 1586 1592 92 e1
85. J. Grebely, K. Petoumenos, and M. Hellard Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection Hepatology 52 4 2010 1216 1224
86. A. Takaki, M. Wiese, and G. Maertens Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C Nat Med 6 5 2000 578 582
87. E. Kenny-Walsh Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group N Engl J Med 340 16 1999 1228 1233
88. J. Schmidt, R. Thimme, and C. Neumann-Haefelin Host genetics in immune-mediated hepatitis C virus clearance. (Report) Biomark Med 5 2 2011 155 (15)
89. S.I. Khakoo, C.L. Thio, and M.P. Martin HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection Science 305 5685 2004 872 874
90. V. Romero, J. Azocar, and J. Zuniga Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome Mol Immunol 45 9 2008 2429 2436
91. M.A. Montes-Cano, J.L. Caro-Oleas, and M. Romero-Gomez HLA-C and KIR genes in hepatitis C virus infection Hum Immunol 66 11 2005 1106 1109
92. A. Rauch, R. Laird, and E. McKinnon Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection Tissue Antigens 69 Suppl. 1 2007 237 240
93. S. Knapp, U. Warshow, and D. Hegazy Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus Hepatology 51 4 2010 1168 1175
94. T. Poynard, P. Bedossa, and P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 9055 1997 825 832
95. D.l. Thomas, J. Astemborski, and R.M. Rai The natural history of hepatitis c virus infection: Host, viral, and environmental factors J Am Med Assoc 284 4 2000 450 456
96. P.Y. Bochud, T. Cai, and K. Overbeck Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C J Hepatol 51 4 2009 655 666
97. G.L. Davis, M.J. Alter, and H. El-Serag Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2 2010 513 521 21 e1-6
98. S.B. Missiha, M. Ostrowski, and E.J. Heathcote Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors Gastroenterology 134 6 2008 1699 1714
99. M. Wright, R. Goldin, and A. Fabre Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study Gut 52 4 2003 574 579
100. H. Huang, M.L. Shiffman, and S. Friedman A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C Hepatology 46 2 2007 297 306
101. M. Marcolongo, B. Young, and F. Dal Pero A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C Hepatology 50 4 2009 1038 1044
102. E. Trépo, A. Potthoff, and P. Pradat Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease J Hepatol 55 1 2011 38 44
103. E. Patin, Z. Kutalik, and J. Guergnon Genome-wide association study identifies variants associated with liver fibrosis progression in HCV-infected patients J Hepatol 56 Suppl. 2 2012 S551
104. F. Stickel, S. Buch, and K. Lau Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in Caucasians Hepatology 53 1 2011 86 95
105. E. Trepo, P. Pradat, and A. Potthoff Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C Hepatology 54 1 2011 60 69
106. R. Bataller, K.E. North, and D.A. Brenner Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal Hepatology 37 3 2003 493 503
107. A.J. Thompson, P.J. Clark, and M. Zhu Genome wide-association study identifies IL28B polymorphism to be associated with baseline ALT and hepatic necro-inflammatory activity in chronic hepatitis C patients enrolled in the IDEAL study Hepatology 52 4, Suppl. 1 2010 1220A 1221A
108. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 55 2 2011 245 264
109. F. Poordad, E. Lawitz, and K.V. Kowdley 12-week interferon-free regimen of ABT-450/r + ABT-333 + ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders J Hepatol 56 Suppl. 2 2012 S549 S550
110. E. Lawitz, F. Poordad, and K.V. Kowdley A 12-WEEK interferon-free regimen of ABT-450/r, ABT-072, and ribavirin was well tolerated and achieved sustained virological response in 91% treatment-naive HCV IL28B-CC genotype-1-infected subjects J Hepatol 56 Suppl. 2 2012 S7
111. F. Suzuki, K. Ikeda, and J. Toyota Dual oral therapy with the NS5A inhibitor Daclatasvir (BMS-790052) and NS3 protease inhibitor Asunaprevir (BMS-650032) in HCV genotype 1B-infection null responders or ineligible/intolerant to peginterferon/ribavirin J Hepatol 56 Suppl. 2 2012 S7 S8
112. K. Chayama, S. Takahashi, and J. Toyota Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders Hepatology 55 3 2012 742 748
113. E.J. Gane, C.A. Stedman, and R.H. Hyland Once daily PSI-7977 plus RBV: pegylated interferon-Alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3 Hepatology 54 Suppl. 1 2011 377A